

ORDERING INFORMATION | APERIO® Hybrid^{17|21}

Labelled APERIO® Hybrid ^{17 21} Dimensions (mm)	Reference Number	Device Diameter (mm)	Device Length* (mm)	Recommended Vessel Diameter (mm)	Required / Recommended Microcatheters for Delivery (Inch)
2.5 × 16	01-000713	2.5	16	1.0 – 2.0	
2.5 × 28	01-000710	2.5	28	1.0 – 2.0	
3.5 × 28	01-000711	3.5	28	1.5 – 3.0	0.0165 – 0.021 NeuroSlider® 17 DLC NeuroSlider® 21 DLC
4.5 × 30	01-000712	4.5	30	2.0 – 4.0	
4.5 × 40	01-000715	4.5	40	2.0 – 4.0	
4.5 × 50	01-000716	4.5	50	2.0 – 4.0	0.021 – 0.027 NeuroSlider® 21 DLC NeuroSlider® 27 (DLC)
6.0 × 40	01-000717	6.0	40	3.5 – 5.5	
6.0 × 50	01-000718	6.0	50	3.5 – 5.5	

* Average length within intended vessel diameter


All changes or modifications, may they be technical or other, or changes in the availability of products are expressly reserved.
Not available for sale in the United States.



www.3w.de 2205



APERIO® Hybrid^{17|21} Thrombectomy Device



For vessel diameters from 1.0 to 5.5 mm

Effective hybrid cell design

Full length visibility

APERIO® Hybrid^{17|21}

Thrombectomy Device

Perfect Interplay – Safe and efficient

Next generation of the reliable and safe APERIO® Hybrid Thrombectomy Device dedicated to further improve fast and efficient flow restoration – even for distal thrombectomy.

Various combination possibilities to find the optimal setting depending on the anatomy and treatment strategy.

“Treatment of occlusions in distal branches of eloquent brain areas such as the ACA territory is a promising extension of mechanical thrombectomy. The APERIO® Hybrid¹⁷ enables safe treatment of small vessels down to a diameter of 1 mm and its 2.5 mm version easily navigates through a 0.0165” ID microcatheter.”

Dr. Hannes Nordmeyer, radprax at St. Lukas Hospital, Solingen, Germany



Improved

The APERIO® Hybrid²¹ Thrombectomy Device is improved for distal thrombectomy and treatment of vessel diameters from 1.0 mm to 4.0 mm with 0.0165" ID microcatheters.

The APERIO® Hybrid²¹ Thrombectomy Device is the portfolio unification enabling the treatment of vessel diameters from 2.0 – 5.5 mm with 0.021" ID microcatheters.




Improved portfolio

Efficient

Proven and effective hybrid cell design: Smaller closed cells ensure perfect vessel wall apposition and expansion into the clot.

Larger clot catching cells assure good integration of the thrombus.

Integrated anchoring elements (except for device with Ø 2,5 mm) offer additional support for efficient clot retention enabling confident and atraumatic retrieval even in challenging anatomies.




Hybrid cell design

Safe


The sleek electropolished surface in combination with smooth atraumatic design elements enable a gentle and safe retrieval.

The full length visibility of the device leads to maximum control and assurance during procedure.




Full length visibility¹


Treatment with APERIO® Hybrid¹⁷ Thrombectomy Device¹



Pre-treatment
M1, A2-A3, A4 occlusion




Recanalisation of A2-A3
with APERIO® Hybrid¹⁷ 2.5 x 16 mm



Post-treatment
Final result (first pass, TICI 3)

Radiopaque Marker Concept



Three distal device markers
for permanent control of position and opening behaviour

Two radiopaque Nitinol composite wires
featuring full length visibility for precise alignment and additional control during procedure

Two proximal device markers
for precise positioning within the thrombus

The New Fully Radiopaque Aperio Hybrid Stent Retriever: Efficient and Safe? An Early Multicenter Experience

Marius Kaschner¹, Thorsten Lichtenstein², Daniel Weiss¹, Bernd Turowski¹, Lukas Goertz^{2,3}, Claudia Kluner⁴, Marc Schlamann², Christian Mathys^{1,4,5}, Christoph Kabbasch²

OBJECTIVE: To investigate the visibility, safety, and efficacy of the full-length radiopaque Aperio Hybrid stent retriever (APH) in mechanical thrombectomy of large vessel occlusions.

METHODS: Multicentric retrospective analysis of patients with stroke, treated with the APH due to an acute ischemic stroke by large vessel occlusions in the anterior or posterior circulation, was performed. We focused on technical and angiographic parameters including device visibility, perfusion results (modified thrombolysis in cerebral infarction scale [mTICI]), procedural times, peri-procedural complications, and favorable clinical outcome (modified Rankin Scale, 0–2) at discharge and after 90 days.

RESULTS: A total of 48 patients (male: n = 22, 45.8%, mean age 73 years [standard deviation (SD), ±15], median baseline National Institutes of Health Stroke Scale: 15 [2–36], n = 25, 52.1% received additional intravenous thrombolytics) were treated with the APH with a mean number of 2 device passes (SD, +3) in APH-only cases (n = 41). The median time from groin puncture to the final mTICI was 54 minutes (SD, +33). In 46 patients (95.8%), mTICI 2b–3 was achieved (mTICI 2c, 12.5%; mTICI 3, 47.9%).

Key words

- Aperio Hybrid
- Ischemic stroke
- Mechanical thrombectomy
- Recanalization
- Stent retriever

Abbreviations and Acronyms

APH: Aperio Hybrid stent retriever

ARISE II: Analysis of Revascularization in Ischemic Stroke with EmboTrap

ASPECTS: Alberta Stroke Program Early CT Score

CT: Computed tomography

DFT: Drawn filled tubing

IVT: Intravenous thrombolysis

LVO: Large vascular occlusions

mRS: Modified Rankin Scale

MT: Mechanical thrombectomy

mTICI: Modified thrombolysis in cerebral infarction

NIHSS: National Institutes of Health Stroke Scale

RCT: Randomized controlled trial

Favorable outcome (modified Rankin Scale <2) was achieved in 15 (32.6%) patients at discharge and in 11 of the 30 (36.7%) patients available for 90-day follow-up. Symptomatic intracranial hemorrhage was recorded in 3 of 48 cases (6.3%). Difficulties during device delivery and/or deployment occurred in 6.3% (3 of 48). APH-related adverse events did not occur. APH radiopacity was rated as good and very good in 97.9% (47 of 48).

CONCLUSIONS: Mechanical thrombectomy with the APH appeared feasible, efficient, and safe. Full-length device radiopacity may facilitate thrombectomy or support to adapt the course of action during retrieval, if required.

INTRODUCTION

Mechanical thrombectomy (MT) in acute ischemic stroke treatment caused by large vascular occlusions (LVO) has evolved into the gold standard of care.^{1,2} Mechanical retrieval of the vessel occluding clot may lead to reliable and fast vessel recanalization. The superiority of stent-retriever-based thrombectomy over intravenous thrombolysis (IVT) alone was demonstrated in numerous large, randomized,

SAH: Subarachnoid hemorrhage

SICH: Symptomatic intracranial hemorrhage

From the ¹Medical Faculty, Department of Diagnostic and Interventional Radiology, University Duesseldorf, Duesseldorf; ²Institute for Diagnostic and Interventional Radiology, and ³Center for Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne; ⁴Institute of Radiology and Neuroradiology, Evangelisches Krankenhaus, University of Oldenburg; and ⁵Research Center Neurosensory Science, Carl von Ossietzky Universitaet Oldenburg, Oldenburg, Germany

To whom correspondence should be addressed: Christoph Kabbasch, M.D.
[E-mail: christoph.kabbasch@uk-koeln.de]

All listed authors contributed to the work. M. Kaschner and T. Lichtenstein contributed equally and share first authorship. C. Mathys and C. Kabbasch contributed equally and share the last authorship.

Citation: World Neurosurg. (2020).

<https://doi.org/10.1016/j.wneu.2020.05.104>

Journal homepage: www.journals.elsevier.com/world-neurosurgery

Available online: www.sciencedirect.com

1878-8750/\$ - see front matter © 2020 Elsevier Inc. All rights reserved.

recanalization appear to be in the range of comparable stent-retriever publications.

Full structural radiopacity would allow a more targeted deployment of the APH and delineation of the stent retriever. From a procedural point of view, visualization of just the distal markers would be sufficient but a reliable detection of clot integration and clot displacement requires full-length visibility of the stent structures. Moreover, during retrieval there is no visual control of the clot-stent interaction in conventional nitinol retrievers as the predecessor Aperio. Compared with the Aperio, the APH is one of few stent retrievers that allow visualization of the clot-strut interaction during both deployment and retrieval.^{11,12} As a result of full-length visibility, a potential failure of the thrombectomy maneuver might be detected at an early stage and enables us to adapt or modify the procedure, for example, obvious nonintegration of the clot within the stent retriever just sliding past it or visible straightening of the target vessel without relative movement of the stent retriever that may indicate increased force transmitted to the vessel, with the risk of structural damage. In our cases in which pushability of the device was rated as "poor" and "very poor" (4.2%, 2 of 48) and positioning of the APH as "poor" (2.1%, 1 of 48), the added DFT wires were supposed to increase the resistance during the delivery and deployment of the APH stent retriever via the microcatheter. This assumption is in accord with reports of an international survey performed among the members of the World Federation of Interventional and Therapeutic.²³ In this context, a final assessment of friction or resistance during delivery and deployment of the device, and evaluation of the used material in combination

with the APH (e.g., microcatheters, aspiration catheters), should be subject to a prospective evaluation.

CONCLUSIONS

This early multicenter experience demonstrated that the recently introduced APH yielded high rates of favorable and excellent reperfusion in cerebral LVO in conjunction with lesional aspiration in the setting of acute stroke. Clinical outcome after 90 days seems to be in line with published literature. The absence of device-related procedural complications reflects a high safety profile. Full-length visibility of the APH may allow the detection of the alignment of the device with the clot and may guide procedural adaptation by control of the actual stent-clot or stent-vessel interaction. These promising initial results will be further evaluated in a German multicentric registry.

CRedit AUTHORSHIP CONTRIBUTION STATEMENT

Marius Kaschner: Writing - original draft, Data curation, Investigation. **Thorsten Lichtenstein:** Writing - original draft, Data curation, Investigation. **Daniel Weiss:** Data curation, Formal analysis. **Bernd Turowski:** Data curation, Formal analysis. **Lukas Goertz:** Data curation, Formal analysis. **Claudia Kluner:** Data curation, Formal analysis. **Marc Schlamann:** Data curation, Formal analysis. **Christian Mathys:** Writing - review & editing, Data curation, Project administration, Investigation, Validation, Supervision. **Christoph Kabbasch:** Conceptualization, Writing - review & editing, Data curation, Project administration, Investigation, Validation, Supervision.

REFERENCES

1. Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO)—European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke [e-pub ahead of print]. *J Neurointerv Surg* <https://doi.org/10.1136/neurintsurg-2018-014569>, accessed February 16, 2020.
2. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2018;49:E46-E100.
3. Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015;372:11-20.
4. Campbell BCV, Mitchell PJ, Kleining TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015;372:1009-1018.
5. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015;372:1019-1030.
6. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015;372:2285-2295.
7. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* 2015;372:2296-2306.
8. Riedel CH, Zimmermann P, Jensen-Kondering U, Stengele R, Deuschl G, Jansen O. The importance of size. *Stroke.* 2011;42:1775-1777.
9. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med.* 2018;378:11-21.
10. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med.* 2018;378:708-718.
11. Pfaff J, Rohde S, Engelhorn T, Doerfler A, Bendszus M, Möhlenbruch MA. Mechanical thrombectomy using the new Solitaire™ Platinum stent-retriever: reperfusion results, complication rates and early neurological outcome. *Clin Neuroradiol.* 2019;29:311-319.
12. Kabbasch C, Mpotsaris A, Chang D-H, et al. Mechanical thrombectomy with the Trevo ProVue device in ischemic stroke patients: does improved visibility translate into a clinical benefit? *J Neurointerv Surg.* 2016;8:778-782.
13. Kaschner MG, Weiss D, Rubbert C, et al. One-year single-center experience with the Aperio thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome. *Neur Sci.* 2019;40:1443-1451.
14. Humphries W, Hoit D, Doss VT, et al. Distal aspiration with retrievable stent assisted thrombectomy for the treatment of acute ischemic stroke. *J Neurointerv Surg.* 2015;7:90-94.
15. Zaidat OO, Castonguay AC, Nogueira RG, et al. TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry. *J Neurointerv Surg.* 2018;10:516.
16. Brouwer PA, Yeo LLL, Holmberg A, et al. Thrombectomy using the EmboTrap device: core laboratory-assessed results in 201 consecutive patients in a real-world setting. *J Neurointerv Surg.* 2018;10:964.
17. Kabbasch C, Mpotsaris A, Liebig T, et al. First-in-man procedural experience with the novel EmboTrap® revascularization device for the treatment of ischemic stroke—a European multicenter series. *Clin Neuroradiol.* 2016;26:221-228.
18. Zaidat OO, Bozorgchami H, Ribó M, et al. Primary results of the multicenter ARISE II study (Analysis

- of Revascularization in Ischemic Stroke with EmboTrap). *Stroke*. 2018;49:1107-1115.
19. Yi HJ, Lee DH, Kim SU. Effectiveness of Trevo stent retriever in acute ischemic stroke. *Medicine*. 2018;97:e10747.
 20. Zaidat OO, Castonguay AC, Gupta R, et al. North American Solitaire Stent Retriever Acute Stroke registry: post-marketing revascularization and clinical outcome results. *J Neurointerv Surg*. 2014;6:584.
 21. Singer OC, Haring H-P, Trenkler J, et al. Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. *Cerebrovasc Dis*. 2013;30:437-445.
 22. Kallenberg K, Solymosi L, Taschner CA, et al. Endovascular stroke therapy with the Aperio thrombectomy device. *J Neurointerv Surg*. 2016;8:834.
 23. Berg R van den, Mayer TE. International survey on neuroradiological interventional and therapeutic devices and materials. *Interv Neuroradiol*. 2015;21:646-652.
- Conflict of interest statement:* C. Kabbasch reports personal fees from Acandis and personal fees from Microvention, outside the submitted work. The remaining authors have no conflicts to report.
- All data will be made available on request in an anonymized manner.
- Received 24 March 2020; accepted 12 May 2020
- Citation: World Neurosurg. (2020). <https://doi.org/10.1016/j.wneu.2020.05.104>
- Journal homepage: www.journals.elsevier.com/world-neurosurgery
- Available online: www.sciencedirect.com
- 1878-8750/\$ - see front matter © 2020 Elsevier Inc. All rights reserved.